Skip to Content

Press Releases

Press Releases

Sutro Biopharma Reports Third Quarter 2018 Financial Results
November 14, 2018
-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2018 /PRNewswire/ --  Sutro Biopharma, Inc.  (NASDAQ: STRO), a clinical-stage drug
Sutro Biopharma Announces $85.0 Million Initial Public Offering
September 26, 2018
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. , a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF™, to create a broad variety of optimally
Sutro Biopharma Announces $85.4 Million Series E Round
July 26, 2018
-Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement- -A Boost for Next-Generation Protein Therapies-   SOUTH SAN FRANCISCO, Calif., July 26, 2018 /PRNewswire/ --  Sutro Biopharma, Inc.,  has secured $85.4 million in Series E financing to advance its wholly-owned
SutroVax Announces $85M Series C Financing led by TPG Growth
June 7, 2018
- Provides growth capital to advance pneumococcal vaccine to clinic and beyond - Preeminent executive vaccinologist, Moncef Slaoui, appointed Board Chairman - Strategic alignment established with Lonza Pharma & Biotech to create end-to-end supply chain FOSTER CITY, Calif., June 7, 2018 /PRNewswire/